Laura Lema
Madrid, MD 28041, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer.
Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer.
Journal: International journal of molecular sciences
Published: March 27, 2026
Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.
Journal: Breast cancer research and treatment
Published: December 22, 2025
Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.
Journal: ESMO open
Published: December 17, 2025
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.
Journal: Breast cancer research and treatment
Published: November 04, 2025
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 25, 2025
Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation.
Journal: Cancers
Published: April 11, 2025
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 27, 2024
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.
Journal: NPJ breast cancer
Published: September 28, 2024
Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 29, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
Journal: Breast cancer research and treatment
Published: March 01, 2024
Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: March 26, 2023
Showing 1-11 of 11
Last Updated: 09/26/2026